Best practice portal main page
Pre-exposure prophylaxis of HIV in adults at high risk (PreP) to reduce HIV acquisition
Summary of the evidence
Pre-exposure prophylaxis of HIV in adults at high risk was found in an evidence review (NHS, 2016) to be effective in:
- reducing the relative risk of acquiring HIV infection by the following amounts in men or transgender women who have sex with men,
- 44 % compared with placebo (1RCT ‘iPrEx’, n=2 441; Truvada given daily; number needed to treat [NNT] 62 per year)
- 86 % compared with no prophylaxis (1 RCT ‘PROUD’, n=523; Truvada given daily; NNT 13 per year)
- 86 % compared with placebo (1 RCT ‘IPERGAY’, n=400; Truvada given 'on demand'; NNT 18 per year)
- reducing the relative risk of acquiring HIV infection in serodiscordant heterosexual couples by 75 % compared with placebo (1 RCT ‘Partners PreP’, n=3 136, once-daily Truvada, mITT population; NNT 68 per year).
